When at first you don't succeed: Sequential strategies for antidepressant nonresponders

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 13, 1997, Pages 23-29

  Thase, Michael E ^a   Rush, A John ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLASSIFICATION; CONFERENCE PAPER; DEPRESSION; DRUG CHOICE; ELECTROCONVULSIVE THERAPY; HUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; SOCIAL SUPPORT; TREATMENT FAILURE; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DRUG RESISTANCE; HUMANS; PATIENT COMPLIANCE; PSYCHOTHERAPY; SOCIAL SUPPORT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0031464430     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Depression Guideline Panel. Clinical Practice Guidelines: Depression in Primary Care, vol 2: Treatment of Major Depression. Rockville, Md: US Dept of Health and Human Services; 1993. Agency for Health Care Policy and Research publication 93-0551
2. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;150(4, suppl):1-26
3. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097
4. Basco MR, Rush AJ. Compliance with pharmacotherapy in mood disorders. Psychiatry Ann 1995;25:78-82
5. Thase ME, Kupfer DJ. Characteristics of treatment resistant depression. In: Zohar J, Belmaker RH, eds. Treating Resistant Depression. New York, NY: PMA Publishing; 1987:23-45
6. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992;149:733-745
7. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-436
8. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
9. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163:30-34
10. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
11. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995;152: 1500-1503
12. Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11
13. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995; 56:30-34
14. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
15. Joffe RT, Levitt AJ, Sokolov STH, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
16. Zarate CA Jr, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57:67-71
17. Ferguson J, Cunningham L, Merideth C, et al. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry 1994;6:153-160
18. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
19. Clerc GE, Ruimy P, Verdeau-Pilles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
20. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
21. Goodnick PJ, Extein IL. Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1989;1:119-122
22. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393
23. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42
24. Armitage R, Rush AJ, Trivedi M, et al. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994;10:123-127
25. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-465
26. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-38
27. Thase ME, Keller MB, Gelenberg AJ, et al. Double-blind crossover antidepressant study: sertraline versus imipramine [abstract]. Psychopharmacol Bull 1995;31:535
28. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241-251
29. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
30. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
31. Fontaine R, Ontiveros A, Eli R, et al. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. Biol Psychiatry 1991; 29:946
32. Bauer M. The combined use of lithium and SSRIs. J Serotonin Res 1995;2: 69-75
33. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid eye improvement of depressed patients treated with serotonin reuptake inhibitors [letter]. Arch Gen Psychiatry 1994;51:248-251
34. Blier P, Bergerson R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15:217-222
35. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 1991;3:209-213
36. Zajecka JM, Jeffriess H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995;56:338-343
37. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;250:118-123
38. Nolen WA, Haffmans PMJ, Bouvy FF, et al. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-197
39. Nolen WA, Van De Putte JJ, Dijken WA, et al. Treatment strategy in depression, II: MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78: 676-683
40. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: a double-blind, cross-over study of tranylcypromine in anergic bipolar depression. Am J Psychiatry 1992;149: 195-198
41. Sackheim HA, Prudic J, Devanand DP. Treatment of medication resistant depression with electroconvulsive therapy. In: Tasman A, Goldfinger S, Kaufman CA, eds. American Psychiatry Press Review of Psychiatry, vol. 9. Washington, DC: American Psychiatric Press; 1990:91-115
42. Fink M. Electroconvulsive therapy. In: Paykel ES, ed. Handbook of Affective Disorders. New York, NY: Guilford Press; 1992:359-367
43. Sackheim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 1990;10:96-104
44. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
45. Thase ME, Howland RH. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann 1994;24:232-240
46. Shapira B, Kindler S, Lerer B. Medication outcome in ECT-resistant depression. Convulsive Ther 1988;4:192-198
47. Hale AS, Procter AW, Bridges PK. Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies. Br J Psychiatry 1987;151:213-217
48. Thase ME. The role of axis II comorbidity in the management of patients with treatment resistant depression. Psychiatr Clin North Am 1996;19: 287-309